Literature DB >> 10337025

Treatment of idiopathic CD4 T lymphocytopenia with IL-2.

C Cunningham-Rundles1, H W Murray, J P Smith.   

Abstract

Idiopathic CD4 T lymphocytopenia (ICL) is an unusual immune defect in which there is an unexplained deficit of CD4 T cells, leading to fungal, parasitic or other serious opportunistic infections. Current treatment efforts are directed at eliminating infections. Here we describe the use of a novel treatment, subcutaneous polyethylene glycol (PEG)-IL-2 injections, in a woman with this disorder, who had chronic severe mycobacterial disease which led to repeated hospitalizations, and advancing respiratory insufficiency. For this patient, PEG-IL-2, 50 000 U/m2, has been given by weekly subcutaneous injections for 5.5 years. This treatment has resulted in marked (and still continuing) long-term immunological improvement with normalized T cell functions and increased CD4 cell numbers. She has had substantial clinical improvement with clearing of mycobacterial disease, reducing hospitalizations and improved lung functions. The improvement seen in this patient suggests that low-dose IL-2 is a safe and practical therapy, which might be useful in other subjects with this potentially serious immune defect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10337025      PMCID: PMC1905283          DOI: 10.1046/j.1365-2249.1999.00886.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Recombinant interleukin 2 therapy in severe combined immunodeficiency disease.

Authors:  R Pahwa; T Chatila; S Pahwa; C Paradise; N K Day; R Geha; S A Schwartz; H Slade; N Oyaizu; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

2.  Acquired immunodeficiency without HIV infection: epidemiology and clinical outcome in Italy. The Italian Study Group on non-HIV AIDS.

Authors:  G Rezza; P Pezzotti; F Aiuti
Journal:  BMJ       Date:  1995-09-23

3.  Brief report: enhanced humoral immunity in common variable immunodeficiency after long-term treatment with polyethylene glycol-conjugated interleukin-2.

Authors:  C Cunningham-Rundles; K Kazbay; J Hassett; Z Zhou; L Mayer
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

4.  Restoration of immunoglobulin secretion in vitro in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2.

Authors:  C Cunningham-Rundles; L Mayer; E Sapira; L Mendelsohn
Journal:  Clin Immunol Immunopathol       Date:  1992-07

5.  Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.

Authors:  J A Kovacs; M Baseler; R J Dewar; S Vogel; R T Davey; J Falloon; M A Polis; R E Walker; R Stevens; N P Salzman; Lane H. Clifford
Journal:  N Engl J Med       Date:  1995-03-02       Impact factor: 91.245

6.  Idiopathic CD4+ T-lymphocytopenia--an analysis of five patients with unexplained opportunistic infections.

Authors:  T J Spira; B M Jones; J K Nicholson; R B Lal; T Rowe; A C Mawle; C B Lauter; J A Shulman; R A Monson
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

Review 7.  Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force.

Authors:  D K Smith; J J Neal; S D Holmberg
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

8.  Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection.

Authors:  D D Ho; Y Cao; T Zhu; C Farthing; N Wang; G Gu; R T Schooley; E S Daar
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

9.  Idiopathic CD4+ T-lymphocytopenia--four patients with opportunistic infections and no evidence of HIV infection.

Authors:  R A Duncan; C F von Reyn; G M Alliegro; Z Toossi; A M Sugar; S M Levitz
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

10.  Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection.

Authors:  H Teppler; G Kaplan; K A Smith; A L Montana; P Meyn; Z A Cohn
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  17 in total

1.  Idiopathic CD4 lymphocytopenia: Pathogenesis, etiologies, clinical presentations and treatment strategies.

Authors:  Hale Yarmohammadi; Charlotte Cunningham-Rundles
Journal:  Ann Allergy Asthma Immunol       Date:  2017-10       Impact factor: 6.347

2.  PCP: thinking beyond HIV.

Authors:  Alexei Gonzalez-Estrada; James Fernandez
Journal:  BMJ Case Rep       Date:  2013-12-05

3.  Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.

Authors:  Dimitrios I Zonios; Judith Falloon; John E Bennett; Pamela A Shaw; Doreen Chaitt; Michael W Baseler; Joseph W Adelsberger; Julia A Metcalf; Michael A Polis; Stephen B Kovacs; Stephen J Kovacs; Joseph A Kovacs; Richard T Davey; H Clifford Lane; Henry Masur; Irini Sereti
Journal:  Blood       Date:  2008-05-02       Impact factor: 22.113

4.  [Adult-onset primary immunodeficiencies].

Authors:  S Gadola; U Salzer; H Schultz; B Grimbacher
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743

5.  Case study documenting the diagnosis of idiopathic CD4+ Lymphocytopenia in a patient with atypical fungal infection (disseminated blastomycosis) by FNA of adrenal mass.

Authors:  Richard H Siderits; Osman Ouattara; Alan Marcus; Hong Guang Gao; Hong Bing Deng; Janusz Godyn
Journal:  Cytojournal       Date:  2010-08-05       Impact factor: 2.091

6.  Idiopathic CD4+ T-cell lymphocytopenia.

Authors:  Aparna Mukherjee; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2009-02-10       Impact factor: 1.967

7.  Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare.

Authors:  T Trojan; R Collins; D A Khan
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

Review 8.  Idiopathic CD4 lymphocytopenia: a case of missing, wandering or ineffective T cells.

Authors:  Dimitrios Zonios; Virginia Sheikh; Irini Sereti
Journal:  Arthritis Res Ther       Date:  2012-08-31       Impact factor: 5.156

9.  Altered responses to homeostatic cytokines in patients with idiopathic CD4 lymphocytopenia.

Authors:  Florence Bugault; Daniela Benati; Luc Mouthon; Ivan Landires; Pierre Rohrlich; Vincent Pestre; Jacques Thèze; Olivier Lortholary; Lisa A Chakrabarti
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

Review 10.  Use of cytokine therapy in primary immunodeficiency.

Authors:  Sumita Roy-Ghanta; Jordan S Orange
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.